Doença hepática gordurosa não alcoólica e cirurgia bariátrica: uma revisão abrangente by Cazzo, E. et al.
UNIVERSIDADE ESTADUAL DE CAMPINAS
SISTEMA DE BIBLIOTECAS DA UNICAMP
REPOSITÓRIO DA PRODUÇÃO CIENTIFICA E INTELECTUAL DA UNICAMP
Versão do arquivo anexado / Version of attached file:
Versão do Editor / Published Version
Mais informações no site da editora / Further information on publisher's website:
https://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802017000300277
DOI: 10.1590/1516-3180.2016.0306311216
Direitos autorais / Publisher's copyright statement:
© by Associação Paulista de Medicina . All rights reserved.
DIRETORIA DE TRATAMENTO DA INFORMAÇÃO
Cidade Universitária Zeferino Vaz Barão Geraldo
CEP 13083-970 – Campinas SP
Fone: (19) 3521-6493
http://www.repositorio.unicamp.br
Sao Paulo Med J. 2017;135(3):277-95     277
REVIEW ARTICLEDOI: 10.1590/1516-3180.2016.0306311216
Nonalcoholic fatty liver disease and bariatric surgery: 
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Doença hepática gordurosa não alcoólica e cirurgia bariátrica: uma revisão abrangente
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ABSTRACT
CONTEXT AND OBJECTIVE: Nonalcoholic fatty liver disease (NAFLD) has been increasingly diagnosed 
worldwide and is now recognized as a source of public health concern. It comprises a wide spectrum of 
histological features that range from simple steatosis to severe forms of fibrosis, steatohepatitis and even 
cirrhosis. The impact of bariatric surgery on the course of NAFLD in individuals with obesity has been 
extensively studied. 
DESIGN AND SETTING: Narrative review; public university hospital.
METHODS: A comprehensive review was conducted based on an online search on the electronic databa-
ses MEDLINE and LILACS using the MeSH terms “fatty liver” and “bariatric surgery”. 
RESULTS: The exact mechanisms that lead to improvement in NAFLD following bariatric surgery are not 
completely understood. Since Roux-en-Y gastric bypass (RYGB) is the bariatric surgical procedure most 
performed worldwide, it is also the one from which the effects on NAFLD have been most studied, althou-
gh there is also consistent evidence regarding the effects from gastric banding, sleeve gastrectomy and 
biliopancreatic diversions. 
CONCLUSION: According to the currently available evidence, bariatric surgery leads to significant impro-
vement in NAFLD. Further research, especially by means of randomized controlled trials enrolling larger 
cohorts of individuals, is needed to determine the optimal procedure for this group of subjects. 
RESUMO
CONTEXTO E OBJETIVO: A doença hepática gordurosa não alcoólica (DHGNA) tem sido diagnosticada 
com maior frequência em todo o mundo na atualidade, sendo agora reconhecida como motivo de pre-
ocupação em saúde pública. Abrange um amplo espectro de alterações histológicas que variam desde 
a simples esteatose até formas graves de fibrose, esteato-hepatite e até cirrose. O impacto da cirurgia 
bariátrica sobre o curso da DHGNA em indivíduos com obesidade tem sido profundamente estudado. 
TIPO DE ESTUDO E LOCAL: Revisão narrativa; hospital universitário público.
MÉTODOS: Uma revisão abrangente da literatura foi conduzida baseada na pesquisa on-line nas bases de 
dados eletrônicas MEDLINE e LILACS por meio dos termos MeSH “fígado gorduroso” e “cirurgia bariátrica”. 
RESULTADOS: Os mecanismos exatos que levam à melhora da DHGNA após a cirurgia bariátrica não são 
completamente conhecidos. Como o bypass gástrico em Y de Roux é a cirurgia bariátrica mais realizada 
em todo o mundo, é também o procedimento cujos efeitos sobre DHGNA foram mais estudados, embora 
haja também evidências consistentes sobre os efeitos de banda gástrica, gastrectomia vertical e deriva-
ções biliopancreáticas. 
CONCLUSÃO: De acordo com as evidências atualmente disponíveis, a cirurgia bariátrica leva à melhora 
significativa da DHGNA. Mais estudos, especialmente por meio de ensaios clínicos randomizados e contro-
lados, recrutando coortes maiores de indivíduos, são necessários para determinar o melhor procedimento 
para esse grupo de pacientes.
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INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD) is defined as accumula-
tion of excessive fat in the liver in the absence of excessive drink-
ing of alcohol and/or any secondary cause.1-3 Along with obesity 
epidemics, it has been increasingly diagnosed over the last few 
decades and is now recognized as a source of public health con-
cern. Today, NAFLD is considered to be the commonest liver dis-
ease worldwide. It comprises a wide spectrum of histological fea-
tures that range from mild steatosis to severe forms of fibrosis, 
steatohepatitis and even cirrhosis.3,4
Epidemiology
Today, the most reliable values for the prevalence of NAFLD 
and nonalcoholic steatohepatitis (NASH) in the general popula-
tion in the Western world are 20-30% and 2-3%, respectively.5-7 
In Asia, the prevalence of NAFLD has been found to range from 
15% to 30% in the general population.8 The reported prevalence 
of NAFLD may vary according to the population studied and 
the diagnostic method used. The results from population-based 
studies provide more accurate data than do autopsies, hospital 
series or studies on high-risk groups, since they avoid higher 
selection bias. Studies that have detected NAFLD by means of 
liver enzyme levels have observed prevalences of NAFLD in the 
general population of between 3% and 23%, i.e. generally lower 
than those reported from analyses that used imaging methods.5-11 
Studies  based on ultrasound scans appear to be more reliable 
and have shown prevalences of NAFLD among healthy adults of 
25-30% in the United States and Italy and 29% in Japan.5-8
NAFLD is associated with significantly higher overall mor-
tality, compared with the general population, particularly due 
to cardiovascular and liver-related complications. The histolog-
ical stage is nevertheless crucial for the longer-term prognosis. 
Among patients with NASH, compared with patients with sim-
ple steatosis, the prevalence of cirrhosis development within the 
first 15 years of follow-up is significantly higher (10.8% versus 
0.7%, respectively) and liver-related mortality is also significantly 
higher (7.3% versus 0.9%). The overall and liver-related mortal-
ity among patients with NASH is correspondingly higher than 
would be expected among individuals of the same age and gen-
der with simple NAFLD.8-11
Among obese populations with metabolic syndrome (MetS) 
and type 2 diabetes mellitus (T2DM), the prevalence of NAFLD is 
much higher, ranging from about 50% to 90%. NAFLD has become 
a challenging public health concern, given that the prevalences 
of obesity and overweight have increased to epidemic levels over 
the last few decades. It constitutes an additional risk factor for this 
group of patients, especially because of the possibility of evolution 
to severe forms of liver fibrosis (including end-stage liver disease 
and cirrhosis) and even liver cancer.5-8,12
Among cases labelled as “cryptogenic cirrhosis”, the preva-
lence of NAFLD appears to be very high. Nayak et al.9 carried out 
a study in which the clinicopathological features of NAFLD were 
explored through clinical data and by examining the explanted livers 
of living-donor liver transplant recipients. Among 103 adult liver 
transplant recipients with different types of chronic liver disease, 
30 had a pre-liver transplantation diagnosis of cryptogenic cirrho-
sis. Out of these 30 cryptogenic cirrhosis cases, 19 (63.3 %) were 
finally labeled as NAFLD-related cirrhosis and showed histologi-
cal features that differed in several respects from those reported 
for the early and established phases of NAFLD.
The risk factors for development of NAFLD have been estab-
lished. Increasing age presents a direct correlation with the prev-
alence of NAFLD. This is possibly related to the increasing insu-
lin resistance and incidence of metabolic syndrome that occurs 
with age.12 NAFLD generally occurs at a higher rate among men 
than among premenopausal women. It also differs according 
to ethnicity, such that it affects 45% of Hispanic people, 33% of 
Caucasians and 24% of African-Americans in the United States 
and has been recorded at higher levels among South Asians in the 
United Kingdom.7-12 Likewise, among children and adolescents, 
the prevalence of NAFLD again seems to differ between different 
ethnic groups, with the highest prevalence in Hispanic people.5
Several studies have revealed high rates of NAFLD among obese 
populations who undergo bariatric surgery.13-17 Reports on morbidly 
obese populations have shown that the prevalence of liver fibrosis 
ranges from 6% to 74.4% and steatohepatitis from 26% to 55%.16,17
Pathophysiology
The underlying mechanisms that are present in the develop-
ment of NAFLD are not completely understood, although much 
progress has been made over recent years. The classical pathoge-
netic pathway that leads to NAFLD was described as the “two-
hit hypothesis”. This theory stated that damage to the liver tissue 
begins through triglyceride accumulation (the first hit), which 
functions as a sensitizing factor for secondary damage caused 
by inflammatory mediators (mainly cytokines or adipokines), 
mitochondrial dysfunction and oxidative stress (the second hits). 
These secondary aggressions would lead to steatohepatitis and 
fibrosis.18,19 Today, it is widely recognized that free fatty acids 
(FFAs) also play a direct role in promoting liver injury. One of the 
consequences of insulin resistance (IR) is greater influx of FFAs to 
the liver: these undergo β-oxidation or esterification with glycerol 
to form triglycerides. Additionally, FFAs are able to cause toxicity 
through directly increasing oxidative stress and activating inflam-
matory pathways.20,21 Another “hit” that was recently identified 
consists of impaired hepatocyte proliferation. In NAFLD, when 
cell death occurs in the liver tissue, oxidative stress causes disrup-
tion to the regenerative process, thus leading to proliferation of 
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hepatic progenitor (oval) cells. The size of the oval cell population 
correlates directly with the degree of fibrosis and it is believed that 
activation of these cells is involved in hepatic carcinogenesis.18,21-23
In NAFLD, lipid accumulation within the liver (steatosis) may 
result from several mechanisms: increased fat synthesis, increased 
fat delivery, decreased fat export and/or decreased fat oxidation.23-28
IR plays an important role in NAFLD development and evo-
lution, and NAFLD also contributes towards worsening of IR. 
In individuals with IR who present excess visceral fat, the influx 
of FFAs to the liver is increased, thus leading to both triglyceride 
accumulation and direct lipotoxicity. On the other hand, several 
abnormalities intrinsic to NAFLD impair insulin receptor signal-
ing, especially FFAs, tumor necrosis factor-alpha (TNF-α), nuclear 
factor kappa B (NF-κB), ceramide, Jun N-terminal kinase 1 (JNK1), 
suppressors of cytokine signaling (SOCS) and cytochrome CYP2E1. 
The cumulative effect generates a vicious cycle of IR and NAFLD 
worsening each other.18,23,29-31
Steatosis is strongly associated with chronic hepatic inflamma-
tion, an effect that is partly mediated by activation of the Iκκ-β/NF-κB 
signaling pathway. This is associated with elevated hepatic expres-
sion of inflammatory cytokines such as TNF-α, interleukin-6 (IL-
6) and interleukin 1-beta (IL-1β), and activation of Kupffer cells. 
Both serum and hepatic levels of TNF-α are elevated in patients 
with NASH, and these levels are correlated with histological sever-
ity.18,32-35 In addition to the proinflammatory effect, TNF-α pro-
motes IR. Further data suggests that inflammation and NF-κB 
activation may also promote carcinogenesis and that this chronic 
inflammatory state may also play a key role in hepatocellular car-
cinoma (HCC) development.18,36,37
Increased leptin levels are observed in cases of obesity and 
NAFLD. These are usually regarded as states of leptin resistance. It is 
possible that leptin may have an important role in the pathogen-
esis of NAFLD. Conversely, the circulating levels of adiponectin 
are inversely proportional to body fat content and become reduced 
in patients with NAFLD.38-41
Oxidative stress and mitochondrial dysfunction play a well-
reported role in NASH, with a direct correlation between the degrees 
of oxidative stress and the severity of liver disease. Structural mito-
chondrial abnormalities and impairment of mitochondrial respi-
ratory chain activity have been reported in human studies.18,42-46 
Endoplasmic reticulum (ER) stress and endotoxemia derived 
from the gut microbiota are other mechanisms that appear to be 
implicated in NASH pathogenesis. ER stress is associated with 
various types of biological stress, such as hyperinsulinemia and 
hyperlipidemia, and it usually causes IR, inflammation, apoptosis 
and mitochondrial dysfunction, through several mechanisms. In 
cases of alcohol-related steatohepatitis, ER stress is a well-estab-
lished pathophysiological factor, but further study on the possible 
role that it plays in the development of NASH is needed.18 
The role of gut bacterial overgrowth in the pathogenesis of 
NASH is now emerging through recent evidence. Bacterial over-
growth leads to production of ethanol and release of bacterial 
lipopolysaccharides, both of which can activate TNF-α produc-
tion in Kupffer cells, thereby inducing inflammation in liver tis-
sue. Individuals with NASH more frequently present bacterial 
overgrowth in the small intestine and increased gut permeability 
than do controls. These findings also suggest that this is a possible 
explanation for the rapid onset of NASH and liver fibrosis follow-
ing jejunoileal bypass surgery. Furthermore, there is evidence that 
hepatic inflammation can be reduced by means of changes to the 
gut microbiota induced by antibiotics and probiotics.47-56
Under high levels of oxidative stress, which is a feature usu-
ally observed in the presence of injurious factors such as NASH 
and viral infection, mature hepatocytes may present impairment 
of their replication process, thus leading to reduction of their pro-
liferative ability. Subsequently, hepatic progenitor cells (HPCs) are 
recruited; these cells have the capacity to differentiate into either 
hepatocytes or cholangiocytes and may be involved in carcino-
genesis relating both to hepatocellular carcinoma and to cholan-
giocarcinoma. Initial research has observed that there is a strong 
association between expansion of HPCs and a ductular reaction 
in liver biopsy specimens in NASH cases. The extent of ductular 
reactions in turn strongly correlates with the degree of fibrosis, 
thus suggesting that HPC expansion/ductular reaction may play 
an important role in stimulating progressive periportal fibrosis.57-60
Histopathology
NAFLD encompasses a wide spectrum of liver histopathological 
abnormalities that may also have highly variable natural courses. 
It is grossly divided into two main categories: simple steatosis, in 
which only hepatocellular steatosis is observed; and NASH, in 
which necroinflammatory reactions are associated with hepato-
cellular steatosis. Simple steatosis usually presents a benign course. 
NASH, on the other hand, is a progressive disease that can evolve 
into liver cirrhosis and HCC. Steatohepatitis-associated hepatocel-
lular carcinoma (SH-HCC) is a variant of classical HCC in which 
the onset appears to be strongly linked to NASH.61,62 
It is important to emphasize that NAFLD/NASH presents a 
different pattern in pediatric individuals, with lesions that may 
or may not resemble those observed in adults. It constitutes an 
area of ongoing investigation within pathology.61,62 Since pediatric 
NAFLD is not the focus of this review, it will not be tackled here.
Histopathological features of adult NAFLD
Hepatocellular steatosis is the hallmark of NAFLD; steatosis in 
more than 5% of the hepatocytes is required for the diagnosis of 
NAFLD.61,63,64 Steatosis may be macrovesicular or microvesicular; 
in NAFLD, the macrovesicular type is usually present, although 
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about 10% of the cases may also present microvesicular steatosis. 
It usually begins in zone 3 and may evolve to panacinar steatosis 
in severe cases.61,65,66
Mild intralobular inflammation is present in NASH and con-
sists of an infiltrate of mixed inflammatory cell types (lymphocytes, 
neutrophils, eosinophils and Kupffer cells). Satellitosis may be spo-
radically observed in NASH and consists of ballooned hepatocytes 
surrounded by polymorphs; this feature is more commonly associ-
ated with alcoholic hepatitis. Lipogranulomas and lobular micro-
granulomas are frequently seen in NASH. Portal inflammation in 
NASH is usually absent or mild; when there is disproportionately 
severe portal inflammation, the possibility of other concurrent 
hepatic diseases needs to be considered.61,67,68
Hepatocellular ballooning is another feature associated with 
NAFLD and is characterized by the presence of swollen hepato-
cytes with rarefied cytoplasm, which may contain fat droplets and 
Mallory-Denk bodies. It usually reflects hepatocellular injury.61
Fibrosis in NASH characteristically follows a perisinusoidal/
pericellular pattern and usually begins in zone 3. Typically, an 
active necroinflammatory reaction is observed, along with fibro-
sis. Progression of perisinusoidal/pericellular fibrosis may lead 
to occurrences of portal/periportal fibrosis, bridging fibrosis and 
liver cirrhosis.69,70
Other important features of NAFLD/NASH include 
glycogenated nuclei, acidophil bodies, Mallory-Denk bodies 
(MDBs), iron deposition and megamitochondria.61,62 Glycogenated 
nuclei are vacuolated nuclei that are usually observed in periportal 
hepatocytes. They are common in NAFLD, but only rarely 
observed in alcohol-induced liver disease.71 Presence of apoptotic 
hepatocytes (acidophil bodies), usually in the sinusoids, is also 
commonly observed in NASH.72 The eosinophilic irregular-shaped 
aggregates that are usually observed in the cytoplasm of ballooned 
hepatocytes in zone 3 are known as MDBs. They are not specific 
to NASH and may be found in alcohol-induced disease, chronic 
cholestasis and HCC.73,74 Mild iron deposition within hepatocytes 
or in the sinusoidal lining cells of the reticuloendothelial system, 
or in both of these, is common in NAFLD/NASH; its significance 
is yet to be fully understood.75 Megamitochondria are massively 
enlarged round or crystal-shaped eosinophilic structures that are 
observed in the cytoplasm of hepatocytes, usually with concurrent 
microvesicular steatosis; they are believed to originate due to lipid 
peroxidation.76 Ductular reactions and presence of an arterial 
branch in zone 3 within perisinusoidal fibrosis are other poorly 
understood abnormalities observed in NASH.59
Diagnosis
According to the current guidelines of the American Association 
for the Study of Liver Diseases (AASLD), there are four require-
ments for diagnosing NAFLD:
1. presence of hepatic steatosis detected using imaging methods 
or biopsy;
2. absence of significant alcohol consumption;
3. absence of possible competing etiologies for hepatic steatosis; 
4. absence of concurrent chronic liver disease.77
There are several noninvasive methods for assessing and diag-
nosing NAFLD, although none of them are able to provide the 
same amount of information that is brought through liver biopsy.78 
Ultrasound scanning is a valuable imaging tool, since it is cheap 
and highly available and may provide overall accuracy of nearly 
80% for detecting NAFLD. On the other hand, it presents limita-
tions that may compromise interpretation of the results, given that 
it is examiner-dependent and there may be technical difficulties 
in performing it on obese individuals because of their anatomical 
features. Thus, although ultrasound provides useful clues towards 
diagnosing NAFLD, it cannot be taken to be the ultimate method 
for detecting it. Moreover, it cannot provide nuanced evaluation 
of the presence of steatohepatitis and the severity of fibrosis.17,79,80 
Ultrasonography-based transient elastography (FibroScan) 
is a promising method that can bring reliable results by means of 
safe examination. However, its cost and low availability compro-
mise its potential impact.17,81 Furthermore, FibroScan has no value 
for patients with ascites and presents great limitations relating to 
examining obese patients, because the probe is calibrated for a 
specific distance between the liver and the chest wall and the low-
frequency vibration induced by the probe and/or the ultrasound 
wave may be strongly attenuated by the fatty tissue.82-84
Development of noninvasive scores for assessing liver disease, 
including NAFLD, is an important field of study nowadays. The ulti-
mate goal in using these scores is to obtain reliable information 
from noninvasive laboratory and clinical variables that are avail-
able in general practice. The NAFLD fibrosis score is the one most 
used today and can easily be calculated based on six readily avail-
able variables: age, body mass index (BMI), hyperglycemia, plate-
let count, albumin and aspartate transaminase/alanine transami-
nase (AST/ALT) ratio. A meta-analysis on 13 studies that enrolled 
3,064 patients showed that the NAFLD fibrosis score yielded an 
area under the receiver operating characteristic curve (AUROC) of 
0.85 for predicting advanced fibrosis (bridging fibrosis or cirrhosis). 
Scores ≤ -1.455 had 90% sensitivity and 60% specificity for ruling 
out advanced fibrosis, whereas scores > 0.676 had 67% sensitivity 
and 97% specificity for identifying the presence of advanced fibro-
sis.85 However, this score does not replace liver biopsy and cannot 
in any manner be regarded as a gold standard, given that it does not 
provide a nuanced evaluation. On the other hand, it does not pro-
duce any morbidity and can be easily and readily assessed through 
routine studies. Thus, this score is quite adequate for population-
based studies and for clinical screening and follow-up purposes.17,84,85
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Despite recent developments in noninvasive methods for assess-
ing NAFLD, liver biopsy remains the gold-standard method for 
diagnosing and characterizing it, since it may provide a nuanced 
evaluation that no other method is capable of today. On the other 
hand, it is expensive and highly invasive, and carries significant 
risk of morbidity and even mortality.77 Moreover, the histological 
features of NAFLD and NASH are unevenly distributed through-
out the entire liver parenchyma, and sampling error might result in 
substantial misdiagnosis and staging inaccuracies.61,78 The current 
guidelines state that use of biopsies should be restricted to indi-
viduals who would benefit the most from diagnostic and therapeu-
tic guidance, and from prognostic perspectives. Hence, a biopsy 
should be considered for NAFLD assessment among patients:
1. with NAFLD, who are at increased risk of development of 
fibrosis and steatohepatitis;
2. with suspected NAFLD, in whom concurrent etiologies for 
hepatic steatosis and/or coexisting chronic liver diseases can-
not otherwise be ruled out.77
Current clinical treatment
The current treatment strategies for NAFLD are based on the var-
ious aspects of its pathophysiology, especially its relationship with 
obesity and insulin resistance. The current nonsurgical strategies 
can be divided in non-pharmacological and pharmacological.
The primary goals of the main nonpharmacological strategies 
are weight loss and lifestyle changes. Interventions based on low-fat 
and low-calorie diets have been evaluated in several studies in which 
it was observed that these diets were associated with reductions in 
liver enzyme levels and liver fat content and improvement in liver 
histology.87-93 Thoma et al. reviewed the efficacy of physical exercise 
alone versus physical exercise combined with dietary approaches 
to reduce liver fat content. Energy restriction and weight reduc-
tion of 4-14% resulted in significant decreases in hepatic steatosis 
of 35-81%. Decreases in liver fat correlated most strongly with the 
degree of weight loss. It was seen that regular exercise might mod-
estly reduce steatosis even without a change in weight.94 However, 
the greatest caveat of interventions that use dietary measures for 
weight loss is their lack of long-term durability. It remains unclear 
how weight regain affects the natural history of NAFLD/NASH.94-97
The primary goal of pharmacological interventions aimed 
towards NAFLD may either be weight loss or consist of a direct 
effect on liver disease and its pathophysiological features, especially 
insulin resistance and inflammation. Evidence regarding the effect 
of weight loss medications on NAFLD is scarce. The results relat-
ing to orlistat were inconclusive in several trials.87,98 Pentoxifylline, 
albeit not targeted for weight loss, led to a slight weight reduction 
and improvement in NASH in one trial.99
Regarding insulin resistance, the potential therapeutic effect of 
insulin sensitizers on NAFLD/NASH has gathered much attention. 
Rosiglitazone was shown to improve steatosis and aminotransferase 
levels in patients with NASH in a randomized controlled trial,100 but 
its use is prohibited in Europe and very restricted in the United States 
because it may increase the risk of ischemic heart disease.101 In ran-
domized controlled trials, pioglitazone induced significant improve-
ments in serum aminotransferase levels and liver histology (steatosis, 
inflammation, ballooning and Mallory-Denk bodies) in individuals 
with NASH.102-104 However, the improvement in the extent of fibrosis 
was not significant. Use of pioglitazone is also prohibited in Europe, 
due to the risk of bladder cancer.101 Use of metformin was not shown 
to provide any benefits or to have any independent therapeutic role in 
individuals with NAFLD, in a meta-analysis study. However, there is 
level III evidence that metformin may have a chemopreventive role 
in patients with diabetes and chronic liver disease, with reductions 
in the incidence of HCC and cholangiocarcinoma.105 Liraglutide, 
an analogue of glucagon-like peptide 1 (GLP-1), was shown to pro-
mote significant improvement in liver histology in individuals with 
biopsy-proven NASH after 48 hours of therapy. Longer-term research 
is needed, but the initial results appear promising.106
Use of vitamin E, because of its antioxidant effects, has shown 
benefits regarding liver histology among non-diabetic individuals 
with NASH. Nonetheless, it is important to emphasize that the safety 
of long-term usage of vitamin E is questionable, since high-dosage 
vitamin E supplements are associated with increased incidence of 
prostate cancer in healthy men, and with all-cause mortality.101,107-110
The current usage of lipid-lowering drugs targeted towards 
NAFLD (mainly statins) is so far unsupported by any substantial 
results from well-conducted studies. Thus, this practice is not rec-
ommended by American guidelines.77,101 The newer agent ezeti-
mibe, which acts through inhibiting cholesterol absorption, has 
shown promising effects, especially in association with acarbose, 
but further results are needed in order to enable its use to be vali-
dated as a current recommendation.111-114
There is a lack of conclusive evidence supporting the use of 
ursodeoxycholic acid, N-3 polyunsaturated fatty acids, angioten-
sin receptor blockers, probiotics and synbiotics as validated treat-
ment options for NAFLD.77,101
OBJECTIVE
The aim of this study was to conduct a critical analysis on the evi-
dence available regarding the effect of bariatric surgery on NAFLD.
METHODS
A review of the literature was conducted through an online 
search for the MeSH terms “fatty liver” and “bariatric surgery” 
in MEDLINE (via PubMed) and LILACS (via BVS) (Table 1). 
We included original studies that reported on clinical trials on 
the effects of several types of bariatric surgery on NAFLD. All the 
papers were checked according to their titles and abstracts 
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(screening). Full papers were obtained from journals available 
through the website of the Commission for Improvement of 
Higher Education Personnel (Comissão de Aperfeiçoamento 
de Pessoal de Nível Superior, CAPES) (Ministry of Education, 
Brazil). Unavailable articles were requested from their authors. 
Articles presenting potentially relevant studies were read and 
analyzed to assess their inclusion criteria. We excluded arti-
cles that consisted of in vitro or animal studies, articles in which 
the participants’ characteristics did not match those mentioned 
above, poster session abstracts, review articles and other types 
of publications (non-standard bariatric surgical techniques; 
studies without appropriate follow-up; studies without appro-
priate NAFLD assessment; or studies with critical method-
ological issues). Other papers were used for contextualization 
and discussion. 
RESULTS
There was significant overlap between the databases. After care-
ful analysis, we selected three systematic reviews, seven prospec-
tive cohort studies and twelve retrospective cohort studies. Table 2 
Table 1. Database search results for the effects of bariatric surgery among individuals with nonalcoholic fatty liver disease, on November 20, 2016
Electronic databases Search strategies Results
MEDLINE (PubMed) (Fatty liver) AND (Bariatric surgery)
3 systematic reviews
7 prospective cohort studies
12 retrospective cohort studies
LILACS (BVS)
((Fatty liver) OR (Hígado graso) OR (Fígado gorduroso)) AND ((Bariatric surgery) OR (Cirurgia 
Bariátrica) OR (Cirurgia Bariátrica))
2 systematic reviews
5 prospective cohort studies
9 retrospective cohort studies
Table 2. Main studies on the influence of bariatric surgery on nonalcoholic fatty liver disease 
N Technique Methodology Mean follow-up (months) Level of evidence Outcome studied Rates of improvement
Silverman et al.115 91 RYGB Retrospective 18.4 2b Biopsy Steatosis: 74%




Liu et al.117 39 RYGB Retrospective 18 2b Biopsy
Steatosis: 96.8%
Fibrosis: 50%
Furuya et al.118 18 RYGB Prospective 24 4 Biopsy
Steatosis: 84%
Fibrosis: 75%
Moretto et al.119 78 RYGB Retrospective 12 2b Biopsy Fibrosis: 31.2%
Vargas et al.120 26 RYGB Retrospective 16 4 Biopsy Steatohepatitis: 84%
Abdennour et al.121 243 RYGB Prospective 12 2b Enzymes Steatosis: 85%
Cazzo et al.122 63 RYGB Prospective 12 2b Fibrosis score Fibrosis: 55%
Luyckx et al.123 69 VBG Retrospective 27 2b Biopsy Steatosis: 54.2%
Stratopoulos 
et al.124
51 VBG Retrospective 18 2b Biopsy
Steatosis: 82%
Fibrosis: 6.2%
Dixon et al.125 36 GB Retrospective 25.6 2b Biopsy
Steatosis: 91.7%
Fibrosis: 83.3%
Phillips et al.126 29 GB Prospective 3 2b MRI Steatosis: 70.4%
Gastaldelli et al.127 159 GB Prospective 12 2b Enzymes Steatosis: 88%
Karcz et al.128 236 SG Prospective 12 2b Enzymes Steatosis: 83%
Algooneh et al.129 84 SG Retrospective 39.6 2b US Steatosis: 56%
Papadia et al.130 99 BPD-S Retrospective 12 2b Enzymes Steatosis: 73%
Ferrer-Marquez 
et al.131




Kral et al.132 104 BPD-DS Retrospective 41 2b Biopsy Fibrosis: 52.9%
Keshishian et al.133 697 BPD-DS Retrospective 12 2b Enzymes Steatosis: 60%
N = number of individuals; RYGB = Roux-en-Y gastric bypass; VBG = vertical banded gastroplasty; GB = gastric banding; SG = sleeve gastrectomy; BPD-S = 
biliopancreatic diversion – Scopinaro; BPD-DS = biliopancreatic diversion – duodenal switch; MRI = magnetic resonance imaging US = ultrasound scan. Levels 
of evidence according to the Oxford classification - 1a: systematic reviews (with homogeneity) of randomized controlled trials; 1b: individual randomized 
controlled trials (with narrow confidence interval); 1c: all or no randomized controlled trials; 2a: systematic reviews (with homogeneity) of cohort studies; 2b: 
individual cohort study or low-quality randomized controlled trials (e.g. < 80% follow-up); 2c: “outcomes” research; ecological studies; 3a: systematic review 
(with homogeneity) of case-control studies; 3b: individual case-control study; 4: case series (and poor quality cohort and case-control studies); 5: expert opinion 
without explicit critical appraisal, or based on physiology, bench research or “first principles”.
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summarizes the main articles found and their respective character-
istics and reported results.115-133
A schematic representation of the search in the online data-
bases and the identification, exclusion and selection of the articles 
is presented in Figure 1.
Bariatric surgery and NAFLD
The impact of bariatric surgery on the course of NAFLD in obese 
individuals has been extensively reported. Surgery plays a signifi-
cant role in the expected natural history of NAFLD and usually 
leads to rapid changes in its evolution. Different surgical methods 
act within this context through a variety of mechanisms, which 
over the long term may be directly associated with the weight loss 
achieved, but over the short to medium term appear to be more 
related to acute structural and endocrine changes that are attrib-
utable to the procedures. Table 1 summarizes the main studies on 
the influence of bariatric surgery on NAFLD.
Roux-en-Y gastric bypass
A pioneering study conducted by Silverman et  al.,115 which 
enrolled 91 individuals, revealed that after Roux-en-Y gas-
tric bypass (RYGB), 65 patients presented reduced steatosis, 18 
patients had no steatosis, 5 patients with minimal steatosis showed 
no change and 3 patients presented increased steatosis. Pre-gastric 
bypass biopsies from 13 patients showed perisinusoidal fibrosis 
(PSF) that was major with bridging in three patients, moderate in 
one patient and slight in nine patients. Following RYGB, PSF was 
found to have been eliminated in 10 patients, was reduced in one 
patient and was the same in two patients. One patient developed 
PSF after gastric bypass.
In a study that evaluated 70 individuals who underwent a vari-
ety of bariatric procedures by means of intraoperative and postop-
erative liver biopsies, Mattar et al.116 observed significant improve-
ment in liver steatosis (from 88% to 8%), inflammation (from 23% 
to 2%) and fibrosis (from 31% to 13%). Inflammation and fibrosis 
resolved in 37% and 20% of the patients, respectively, correspond-
ing to significant improvements of 82% in grade and 39% in the 
stage of liver disease. As expected, purely restrictive procedures 
produced a significantly less dramatic impact on weight loss than 
did gastric bypass. Improvement in grade in the purely restrictive 
group (66% showed improvement in grade) was significantly less 
than in the gastric bypass group (93%).
In a case series that enrolled 16 individuals, Clark et al.134 evalu-
ated liver histology at the time of RYGB surgery and at the time of 
elective incisional hernia repair after weight loss. For all the patients, 
the initial biopsy showed steatosis, while 94% had inflammation, 
88% had ballooning degeneration, 88% had perisinusoidal fibrosis 
and 81% had portal fibrosis. Steatosis improved in 15 out of the 
16 patients, with resolution in 13. Twelve of the 15 patients with 
inflammation at the baseline showed improvement, and 12 out of 
14 showed less ballooning. Six of the 14 patients with perisinu-
soidal fibrosis and 6 of the 13 patients with portal fibrosis showed 
improvement. No patient presented worsening of steatosis, inflam-
mation, ballooning or fibrosis. 
In a historical cohort that enrolled 90 individuals who under-
went liver biopsies during RYGB and one year afterwards, Mottin 
et al.135 observed that the prevalence of hepatic steatosis at the 
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time of the surgery was 87.6%. In the second biopsy, 16 patients 
(17.8%) out of the total had the same degree of steatosis, 25 
(27.8%) presented an improved steatosis pattern and 49 (54.4%) 
had normal hepatic tissue.
In a study on 19 individuals who underwent liver biopsy dur-
ing RYGB that confirmed the presence of NASH and were then 
contacted to undergo a repeat biopsy, Barker et al.136 observed sig-
nificant improvements in steatosis, lobular inflammation, portal 
and lobular fibrosis. Histopathological criteria for NASH were no 
longer found in 17/19 patients (89%). 
In a study that enrolled 16 individuals who underwent liver 
biopsy during primary RYGB and a new biopsy during repairs 
on incisional hernias, Csendes et al.137 observed that 11 out of 
15 patients who had had liver abnormalities returned to a nor-
mal condition or only had minimal change (73.3%); two patients 
(13.3%) showed improvements, one patient presented a slight 
worsening of liver condition and one patient who had presented 
liver cirrhosis showed no change.
de Almeida et al.138 studied 16 individuals who underwent a 
first biopsy during RYGB and another subsequent to the surgery 
(23.5 ± 8.4 months afterwards). They observed complete regression 
of NAFLD in 15 patients (93.7%); complete regression of necroin-
flammatory activity was observed in all patients. Among the four 
patients presenting fibrosis in the first biopsy, complete remission 
was observed in one and improvement in one; two continued to 
show the same degree of fibrosis without evidence of disease activity.
An exploratory study carried out by Klein et al.139 evaluated 
whole-body glucose, fatty acid and lipoprotein kinetics, liver his-
tology and hepatic cellular factors involved in inflammation and 
fibrogenesis in seven severely obese subjects, before and one year 
after RYGB. A decrease in hepatic steatosis was observed, without 
changes in standard histological assessments of inflammation and 
fibrosis. However, there were marked decreases in hepatic factors 
involved in regulating fibrogenesis (collagen-alpha 1, transform-
ing growth factor-beta 1, alpha-smooth muscle actin and tissue 
inhibitor of metalloproteinase 1 expression and alpha-smooth 
muscle actin content) and inflammation (macrophage chemoat-
tractant protein 1 and interleukin 8 expression).
In a retrospective analysis on paired needle liver biopsies taken 
during and following RYGB in 39 patients, Liu et al.117 observed 
that the initial prevalences of hepatic pathological conditions were: 
steatosis (89.7%), hepatocellular ballooning (58.9%) and centrilobu-
lar/perisinusoidal fibrosis (50%). These improved significantly after 
RYGB: steatosis (2.9%), ballooning (0%) and centrilobular fibrosis 
(25%); significant decreases in the lobular inflammation score and 
stage of fibrosis were also noted. Nonetheless, no improvements 
were seen in portal tract inflammation or fibrosis.
A controlled study conducted by Furuya et al.,118 which enrolled 
18 individuals who underwent a wedge biopsy during RYGB and 
a percutaneous biopsy two years later, showed that, after a mean 
excess weight loss of 60%, steatosis disappeared in 84% of the 
patients, fibrosis in 75% and ballooning in 50%. A slight lobular 
inflammatory infiltrate remained in 81%, apparently unrelated to 
fatty degeneration.
Kakizaki et al.140 conducted a prospective study that enrolled 
84 participants, to compare the effects of RYGB on NAFLD in 
Japanese and non-Japanese individuals. They observed that when 
the body mass index (BMI) was similar, liver dysfunction among 
Japanese patients with severe obesity tended to be higher than 
among non-Japanese patients. Japanese patients with severe obe-
sity would therefore need to reduce their body weight to a greater 
degree than would non-Japanese patients with the same BMI. The 
laboratory data and BMI were seen to be significantly improved, 
one year after laparoscopic RYGB, in both groups. 
Tai et al.141 conducted a prospective study that enrolled 
21 patients with morbid obesity who underwent intraopera-
tive liver biopsy and follow-up liver biopsy one year after laparo-
scopic RYGB. They observed statistically significant histological 
improvements in the patients’ NAFLD activity scores (NAS) and 
individual components, including steatosis, ballooning degeneration 
and lobular inflammation. Preoperatively, 4 (19.0%), 11 (52.4%) 
and 6 (28.6%) patients were found to have NAS ≥ 5, 3 to 4, and 
≤ 2, respectively; all patients had NAS ≤ 2 after surgery. The stage 
of fibrosis also presented significant improvement.
A retrospective study by Moretto et al.119 that evaluated 
78 patients with morbid obesity who underwent RYGB and had 
liver biopsies taken during surgery and after weight loss, observed 
that 35 (44.8%) had fibrosis at the time of the first biopsy and 
24 (30.8%) had hepatic fibrosis after weight loss, including 19 of 
the 35 patients (54.3%) with fibrosis at the first biopsy and 5 of the 
43 (11.6%) without hepatic fibrosis at the first biopsy. These authors 
concluded that surgical weight loss among patients with morbid 
obesity was associated with a significant reduction in the preva-
lence of hepatic fibrosis.
In a study on 26 paired biopsies collected during RYGB and at 
an average of 16 months afterwards, Vargas et al.120 reported that 
there were significant improvements in steatosis, lobular and por-
tal inflammation and fibrosis in the second biopsy. Twenty-five of 
the patients (96.1%) presented NASH in their index biopsy, while 
only four (15.3%) of the repeat biopsies fulfilled the criteria for 
NASH. Persistence of fibrosis was observed in five patients at the 
second biopsy. Steatosis and fibrosis at surgery were predictors of 
significant fibrosis post-surgery.
In a large prospective study that enrolled 1236 participants, 
Caiazzo et al.142 compared liver biopsy outcomes following RYGB 
and gastric banding. All NAFLD parameters improved after sur-
gery. They all improved significantly more after RYGB than after 
gastric banding (percentage steatosis: one year, 7.9 versus 17.9; five 
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years, 8.7 versus 14.5; NAS: one year, 0.7 versus 1.1; five years, 0.7 
versus 1.0). In multivariate analysis, the superiority of RYGB was 
primarily but not completely explained by weight loss.
Abdennour et al.121 conducted a prospective study that enrolled 
243 individuals, with the main objective of studying the relation-
ship between white adipose tissue evaluation methods and weight 
loss. These authors also observed significant improvement in liver 
enzymes one year after RYGB.
Cazzo et al.122 conducted a prospective study in which they 
evaluated changes in NAFLD fibrosis score between the time of 
surgery and one year after RYGB. They observed that the mean 
score decreased from 1.142 to 0.066, and that surgery led to a 
resolution rate for advanced fibrosis of 55%. Resolution was sta-
tistically associated with female gender, the percentage of excess 
weight loss, post-surgical BMI, postsurgical platelet count and 
diabetes resolution. 
In an exploratory study that compared 14 RYGB and 9 sleeve 
gastrectomy (SG) patients, Froylich et al.143 observed that all mor-
phological characteristics of NAS improved significantly after RYGB, 
whereas only steatosis and total NAS improved after SG. The state 
of fibrosis improved in both groups, but to a greater degree after 
RYGB. There were no significant differences in the decreases in 
NAS score after RYGB and SG procedures. These exploratory data 
support the idea that a randomized trial should be conducted to 
determine the differential effects of SG and RYGB on NAFLD.
Gastric banding and banded gastroplasty
Luyckx et  al.123 conducted a retrospective clinical analysis on 
69 individuals who underwent liver biopsy during gastroplasty 
and a repeat biopsy later on, during the course of a mandatory 
surgical procedure. They observed that, after the drastic weight 
reduction, 45% of the histological observations were consid-
ered normal. Abnormal fattiness significantly decreased follow-
ing surgery (38% versus 83% before). Furthermore, the sever-
ity of steatosis was significantly reduced in most cases: mild in 
62% versus 21%, moderate in 23% versus 37% and severe in 15% 
versus 42%, after and before weight loss, respectively. However, 
a significant increase in hepatitis was observed, in 26% versus 
14% before. Nevertheless, 87.5% of the cases were graded as mild 
and 12.5% as moderate, while no severe hepatitis was observed. 
The prevalences of fibrosis and cirrhosis remained unchanged. 
Busetto et al.144 examined a case series in which they aimed to 
evaluate visceral fat content following gastric banding. They enrolled 
six premenopausal women with morbid obesity with an ultraso-
nographic diagnosis of liver steatosis and observed that there was 
a statistically significant reduction in visceral adipose tissue, of 
1.0 ± 0.9 liters over the period from 0 to 8 weeks, but only a non-
significant further reduction of 0.6 ± 0.7 liters over the period 
from 8 to 24 weeks. The relative reduction of visceral fat over the 
period from 0 to 8 weeks was greater than the relative reduction 
of total fat. The liver volume also showed a statistically significant 
reduction of 0.24 ± 0.26 liters during the first phase of weight loss, 
corresponding to a relative reduction of 12.3 ± 10.6%. Hence, dur-
ing the period from 8 to 24 weeks, liver volume was substantially 
stable. During the phase of rapid weight loss after gastric surgery, 
preferential mobilization of visceral fat, compared with total adi-
pose tissue, was observed.
Stratopoulos et al.124 conducted a study that enrolled 51 individ-
uals who underwent a biopsy during surgery and a second biopsy 
after an average time of 18 months, and among whom 16 under-
went a third biopsy at an average of 17 months after the second 
one. They reported that, at baseline, steatosis and steatohepatitis 
(mostly grade 3) were present in 98.0% of the subjects and fibrosis 
(mostly stage 2) in 94.1%. After an excess weight loss of 66%, ste-
atosis and steatohepatitis improved significantly. Although a signifi-
cant overall decrease in fibrosis occurred, 21 patients (41.1%) did 
not present any change, while six patients (11.7%) showed increased 
fibrosis. None of the patients developed cirrhosis. The third biopsy, 
performed in 16 of the subjects, showed further significant improve-
ments in liver histology.
Dixon et al.125 examined a case series of 36 selected obese 
patients and evaluated paired liver biopsies: the first at the time 
of laparoscopic adjustable gastric band placement and the second 
after weight loss. The initial biopsies revealed NASH in 23 patients 
and steatosis in 12 patients. Follow-up biopsies were taken at 
25.6 ± 10 months (range, 9-51 months) after band placement. 
There were significant major improvements in lobular steatosis, 
necroinflammatory changes and fibrosis at the second biopsy. 
Portal abnormalities remained unchanged. Eighteen patients had 
an initial fibrosis score of 2 or more, while only three patients 
showed this at the follow-up.
Jaskiewicz et al.145 conducted a study on 10 individuals who 
underwent a wedge biopsy during gastroplasty and had a new repeat 
biopsy eight months later. They observed significant improvements 
of the degenerative and inflammatory hepatic lesions in the repeat 
biopsies and liver function readings, eight months after the surgery.
In a prospective study conducted by Phillips et al.,126 pro-
ton magnetic resonance spectroscopy and magnetic resonance 
imaging were used to estimate the quantities of lipids contained 
within the liver and abdominal subcutaneous and visceral com-
partments of 29 obese individuals, before gastric banding and 
three months afterwards. Significant reductions in body weight, 
abdominal fat and liver fat were observed three months after sur-
gery. Changes in liver fat content were more closely associated 
with changes in serum gamma-glutamyl transferase than with 
changes in waist circumference.
Gastaldelli et al.127 conducted a prospective study that eval-
uated 159 subjects with morbid obesity following laparoscopic 
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adjustable gastric bypass. They observed that one year after gastric 
bypass, the patients’ glucose tolerance, liver function tests and IR 
had improved; ferritin had not changed significantly but was still 
correlated with IR. The authors concluded that ferritin might be an 
additional useful marker for cases of hepatic IR of greater severity.
A prospective study by Moschen et al.,146 in which 30 indi-
viduals who underwent gastric bypass were enrolled, showed 
that the surgery improved IR, abnormal liver function tests and 
liver histology. Pronounced weight loss after 6 and 12 months was 
accompanied by significant increases in serum adiponectin lev-
els, whereas both leptin and visfatin levels decreased. Serum levels 
of resistin increased after 6 months but fell below baseline values 
after 12 months. These results suggest that weight loss after gastric 
bypass surgery improves the adipocytokine milieu towards a more 
anti-inflammatory direction, both systemically and in the liver. 
In a retrospective study that enrolled 16 individuals, 
Swierczynski et al.147 observed significant improvements in sev-
eral laboratory parameters, including serum phenylalanine, ALT, 
lipid concentrations and IR. A strong positive correlation between 
serum phenylalanine and serum ALT concentrations might suggest 
that the deterioration of liver function observed in obese patients 
contributes towards decreased phenylalanine metabolism and con-
sequently towards increased serum phenylalanine concentration.
A prospective study was conducted by Frige et al.148 with the aim 
of comparing the effects of gastric bypass and biliointestinal bypass 
(BIB) on glucose and lipid metabolism in NAFLD. There were 
24 individuals in the gastric bypass group and 12 in the BIB group, 
and a significantly greater decrease in liver enzymes (ALT) was 
observed in the gastric bypass patients than in the BIB group.
Sleeve gastrectomy
In an analysis on prospective data gathered from 236 individuals, 
Karcz et  al.128 observed significant improvements in AST, ALT, 
triglycerides and high-density lipoprotein (HDL) levels one and 
three years after SG. NASH patients showed significant losses of 
body weight and amelioration of NASH status.
A retrospective study was conducted by Algooneh et al.129 
on 84 patients diagnosed with NAFLD prior to undergoing SG. 
The diagnosis of NAFLD was achieved based on ultrasonographic 
imaging. A total of 47 patients (56%) showed complete resolution 
of NAFLD postoperatively. Multivariate analysis showed that there 
was significant resolution of NAFLD among the patients who 
achieved > 50% excess weight loss, after controlling for age and sex.
A prospective study conducted by Coupaye et al.,149 primar-
ily to compare the nutritional effects of SG with those of RYGB, 
with 30 individuals in each group, also observed that transaminase 
levels were significantly lower after RYGB than after SG. This sug-
gested that alterations in liver metabolism might affect synthesis 
or catabolism of some circulating lipids and proteins after RYGB.
Billeter et al.150 conducted a retrospective matched study on 
a prospective database, to compare the effects of RYGB and SG 
on 34 individuals with morbid obesity. Both procedures signifi-
cantly lowered ALT and aspartate aminotransferase (AST) after 
12 months, but SG improved both liver function tests signifi-
cantly better than RYGB did. In contrast to RYGB, SG normal-
ized elevated ALT levels completely. In a study comparing 30 
individuals who underwent paired liver biopsies during surgery 
and six months afterwards, Praveen-Raj et al.151 reported that the 
individuals who underwent SG presented non-significant greater 
improvement of liver histology than those who underwent RYGB.
Biliopancreatic diversions
Scopinaro operation
In a retrospective analysis on 99 consecutive individuals who 
underwent surgery, Papadia et  al.130 noticed that AST levels at 
two months were significantly higher and then were signifi-
cantly lower at 12 months. Hepatocellular necrosis in this series 
peaked at two months and decreased thereafter. The weight loss 
at two months, preoperative body weight, glucose levels and 
hepatic histology seemed to be of help in identifying patients at 
increased risk of acute liver damage, thus prompting the need 
for enhanced surveillance.
Ferrer Márquez et al.131 conducted a prospective study on 
76 obese individuals who underwent biopsy during surgery and 
12-24 months afterwards. They observed that there was a signifi-
cant decrease in overall NAFLD, with decreased inflammation and 
fibrosis. No cases of liver failure were observed. 
Duodenal switch
In an analysis on 104 individuals who underwent the duodenal 
switch procedure and required further reoperation, Kral et al.132 
observed that severe fibrosis (grade 3-5) decreased in 28 whereas 
mild fibrosis (grade 1-2) appeared in 42. Increased fibrosis was 
related to low-normal serum albumin, uncontrolled diarrhea, low 
intake of alcohol and menopausal status. Fibrosis and inflamma-
tion significantly decreased over time. The 11 patients with cir-
rhosis exhibited decreases in fibrosis, from a mean of grade 5 to 
grade 3, as well as reduced levels of inflammation, Mallory bodies 
and glycogenated nuclei. Seven patients presented disappearance 
of nodules and fibrous bridging, while two showed regression. 
Keshishian et al.133 conducted a retrospective analysis on 697 
individuals who underwent laboratory tests 6, 12 and 18 months 
after surgery. All of them underwent liver biopsies during duode-
nal switch surgery and 78 individuals underwent a second surgical 
procedure at least six months after the primary duodenal switch. 
Transient elevation of liver enzymes at six months was observed; 
this was seen to have normalized at 12 and 18 months. A three-
grade progressive improvement in the severity of NASH and a 60% 
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improvement in hepatic steatosis were attained three years after 
the duodenal switch operation. 
In a study on different procedures, Weiner152 analyzed 16 indi-
viduals who underwent biopsy during duodenal switch and in a 
later reoperation. Complete recovery from NAFLD was observed, 
and it was concluded that obesity surgery improved steatosis, 
necroinflammatory activity and hepatic fibrosis in patients with 
morbid obesity and NASH.
Johansson et al.153 conducted a prospective cohort study on 10 
individuals who underwent duodenal switch and 21 cases of RYGB. 
Patients with morbid obesity treated by means of RYGB or duo-
denal switch showed sustained reductions in liver enzyme levels. 
In a retrospective cohort study evaluating the influence of 
duodenal switch surgery on liver enzyme levels over a four-year 
period, among morbidly obese patients with normal aminotrans-
ferase and high baseline aminotransferase levels, Aller et al.154 
reported that significant decreases in ALT and AST activity levels 
occurred. The baseline percentages of high aminotransferase lev-
els and the percentage of ALT/AST ratios that were < 1 were also 
found to be significantly lower at the one, two, three and four-year 
follow-ups in both groups.
Systematic reviews and synthesis
A meta-analysis conducted by Mummadi et al.,157 in which the 
surgical techniques analyzed were mixed, revealed that steatosis, 
steatohepatitis and fibrosis appeared to improve or become com-
pletely resolved in the majority of patients after bariatric surgery-
induced weight loss. These authors emphasized the limitations 
of their study, regarding mainly the vast heterogeneity of the 
overall designs and expected outcomes of the studies included. 
Another meta-analysis, conducted by Bower et  al.,156 revealed 
that bariatric surgery was associated with a significant reduction 
in the weighted incidence of a number of histological features 
of NAFLD, including steatosis (50.2%), fibrosis (11.9%), hepato-
cyte ballooning (67.7%) and lobular inflammation (50.7%); sur-
gery was also associated with a reduction in liver enzyme lev-
els. These authors emphasized that there was high heterogeneity 
among the methodologies and results, a factor that may have lim-
ited their analysis of these findings. A Cochrane review157 that 
specifically addressed the lack of randomized clinical trials and 
high heterogeneity of the studies available acknowledged that the 
improvements regarding steatosis and inflammation seemed to 
be clear. However, it was concluded that the quality of the data 
available did not allow the authors to draw any unbiased conclu-
sion relating to bariatric surgery for treating NASH. Despite the 
limitations of these studies, they represent the best level of evi-
dence currently available on this topic.
There are some major concerns regarding research on the 
effects of bariatric surgery for treating NAFLD that need to be 
emphasized. Firstly, as is common among surgical studies, there 
is a lack of randomized controlled studies; in fact, the majority of 
studies are retrospective and non-controlled, and these aspects may 
produce data of poor quality. Secondly, and specifically regarding 
studies on NAFLD, there is no standardized measurement for the 
outcomes evaluated: some studies have evaluated liver biopsy spec-
imens, while others have compared data from imaging studies or 
noninvasive methods for assessing liver disease. Thirdly, optimal 
evaluation of NAFLD is only possible by means of liver biopsies. 
These can easily and safely be carried out at the time of the pri-
mary surgery, but this procedure is not widely available later on, 
given that it is not risk-free and therefore performing it in indi-
viduals who do not require surgical interventions constitutes an 
ethical concern. This leads to great heterogeneity of outcomes that 
also cannot be ignored. 
Despite the lack of controlled and randomized studies, there 
is a clear trend towards better results with regard to NAFLD out-
comes among obese individuals who undergo surgery. It is also clear 
that the staging of NAFLD at the time of surgery is an important 
predictor of success, since it is noticeable that the rates of resolu-
tion for simple steatosis are much higher than those observed for 
steatohepatitis and especially for fibrosis.
Mechanisms underlying post-surgical improvements in NAFLD
The exact mechanisms that lead to improvement in NAFLD 
following bariatric surgery are probably strongly related to the 
metabolic changes that are involved in amelioration of meta-
bolic syndrome (MetS). These changes occur early after the pro-
cedures, during a phase when no significant weight loss has yet 
been achieved. It is clear that while weight loss plays an important 
role in controlling metabolic abnormalities, this effect appears to 
be more significant over the long term.158-160 Furthermore, there 
is evidence that excess weight is not the main pathophysiological 
feature relating to NAFLD.158
The causes of early improvement of MetS after bariatric sur-
gery are complex and relate to changes on the entero-insular 
axis mediated by gastrointestinal hormones called incretins.160-162 
The anatomical changes caused by the surgical procedures, par-
ticularly duodenal exclusion and overflow of nutrients to the distal 
small bowel, lead to release of incretins, especially glucagon-like 
peptide 1 (GLP-1) and gastrointestinal insulinotropic polypep-
tide (GIP). These increase the production and release of insulin, 
improve peripheral insulin sensitivity and favor an anorexic state. 
Moreover, it appears that surgery enhances adipokine metabolism, 
which probably relates to increasing insulin sensitivity and pro-
motes an anti-inflammatory effect by means of immunomodula-
tion.160 Recent research has indicated that surgery leads to changes 
in the gut microbiota and bile acid circulation that may be benefi-
cial regarding MetS and NAFLD.158-162
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Furthermore, there is a decrease in portal influx of free fatty 
acids following surgery, which may be related both to feeding restric-
tions and to metabolic changes in visceral insulin sensitivity.161,162
International Federation for the Surgery of Obesity and 
Metabolic Disorders (IFSO) position statement
In the most recent IFSO consensus statement,163 it is stated that 
bariatric surgery leads to reversal or significant improvement of 
NAFLD and NASH. Since the vast majority of the studies that 
led to this conclusion were non-randomized, non-controlled and 
observational cohort studies, this postulate constitutes a grade 
B recommendation, with evidence level 2. The IFSO also con-
cluded that, despite the solid evidence available to date, further 
research, especially in randomized controlled settings, is neces-
sary in order to reach ultimate conclusions. The high prevalence 
of NAFLD among the bariatric population also needs to be con-
sidered, as a significant factor.17,164,165 Hence, taking into account 
the overall impact of bariatric surgery on obesity and obesity-
related comorbidities, such as NAFLD, this treatment option 
should be offered to the group of individuals who fulfill the cur-
rent criteria of indications, as a potentially effective therapy.
Bariatric surgery in cirrhotic patients
Despite the increasing prevalence of obesity among the popula-
tion with liver cirrhosis, along with the general epidemic of obe-
sity, the number of studies on this topic is still limited. The main 
factors that need to be taken into account whenever a candidate 
for bariatric surgery is cirrhotic are the presence of portal hyper-
tension and abnormalities of hepatocytic function. Regarding 
obese individuals who are also candidates for liver transplanta-
tion, the choice of technique and optimal timing for perform-
ing bariatric surgery are also significant issues that are not fully 
addressed in the current literature.
Among individuals with severe cirrhosis, surgical morbidity and 
mortality are significantly higher than what is observed in the general 
obese population. A retrospective study by Mosko et al.166 that analyzed 
a national United States database found significantly higher mortality 
rates among cirrhotic individuals, both in those who were clinically 
compensated (0.9%) and in those who were not (16.3%), than among 
non-cirrhotic individuals (0.3%). Moreover, in low-volume centers, 
mortality reached 41% among non-compensated cirrhotic individu-
als. Dallal et al.167 conducted a study that enrolled individuals with 
an incidental intraoperative diagnosis of liver cirrhosis, determined 
during bariatric surgery. They found that, among compensated cir-
rhotic individuals, RYGB presented a mortality rate similar to what 
was observed in the general population. However, it was also observed 
that episodes of transient renal failure, longer operation times and 
greater amounts of intraoperative bleeding and need for transfu-
sion were more common within this group than in the general obese 
population. In a meta-analysis, Lazzati et al.168 observed a mean excess 
weight loss of 66% among morbidly obese cirrhotic individuals over 
a two-year period, which was comparable to the general population. 
SG was the surgical procedure most often performed, and the peri-
operative mortality rate was comparable to what was observed in the 
general population. However, morbidity (especially due to the need 
for reoperations) and mortality during the first year following sur-
gery were significantly higher. The heterogeneity of the studies and 
the small samples analyzed were considered to be major limitations 
of their review, thus not allowing further conclusions.
Among candidates for liver transplantation, the choice of tech-
nique is of major importance, because of two factors: potential impair-
ment of the absorption of immunosuppressive drugs and the pos-
sibility of endoscopic access to the biliary tract. Currently, there are 
no studies analyzing the pharmacokinetics of immunosuppressive 
drugs in liver-transplanted individuals who underwent bariatric sur-
gery, but among kidney transplantation recipients who underwent 
RYGB, there are reports of the need for higher dosages of tacrolimus, 
sirolimus, mycophenolate sodium and cyclosporine.169 Regarding 
access to the biliary tract, post-transplantation biliary strictures 
are common, occurring in up to 17% of the cases.170 Taking these 
situations into consideration, SG appears to be the most appropri-
ate technique for this group of individuals, since it does not affect 
drug absorption and enables endoscopic access to the biliary tract.
The optimal timing for performing bariatric surgery in individ-
uals with cirrhosis who are also candidates for liver transplantation 
is yet to be determined. This surgery may be performed before, after 
or even during the transplantation.171 One significant concern is the 
potential impact of obesity on the outcomes from liver transplanta-
tion. Recently, it was observed that surgical mortality, two-year sur-
vival and graft viability were similar in obese and lean individuals. 
Perioperative morbidity was slightly higher.172,173 Because of the higher 
morbidity and mortality observed among non-compensated liver 
transplantation candidates, the pre-transplantation approach pres-
ents clear limitations. Bariatric procedures performed concomitantly 
with the transplantation have been reported; this approach has the 
potential to minimize the number of surgical procedures in high-risk 
individuals. However, it also requires concomitant availability of both 
surgical teams and generates the risk of combining the complications 
of both procedures.174 Based on this latter finding, although there is 
no consensus yet, the approach that is best accepted is to perform the 
transplantation first and the bariatric surgery later on, among non-
compensated cirrhotic individuals or among those with moderate to 
severe portal hypertension. According to the current literature, the 
morbidity is significantly higher, but the mortality is comparable.175,176
Current situation and future perspectives
NAFLD is becoming a public health concern worldwide today, 
and its prevalence is expected to grow even further in the near 
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future. There is enough evidence to suggest that bariatric sur-
gery should be considered to be the optimal treatment option for 
NAFLD by choice, and no longer only by chance.177 It is expected 
that NAFLD may become the major reason for living-donor 
transplantation in the United States by 2030.178
Although bariatric surgery is currently recognized as the stan-
dard treatment option for morbid obesity and its related comor-
bidities, the number of operations performed is far from suffi-
cient to meet the need for intervention. In fact, less than 500,000 
bariatric surgery procedures are performed worldwide every year 
today. This number represents less than 0.1% of the entire suppos-
edly obese population.179-181 Moreover, there are large numbers of 
subjects who do not fulfill the current indications for surgery but 
present harmful abnormalities relating to fat and glucose metabo-
lism that can lead to and aggravate liver disease. 
Hence, the most practical and effective action that can be 
implemented in relation to this entire disease chain is preven-
tion. Encouragement towards practicing physical activity and fol-
lowing healthy low-fat/low-calorie diets needs to be extensively 
included in educational and community programs as early in life 
as possible, since obesity has become a pediatric issue too.179,180 
Continuing education for healthcare professionals regarding liver 
disease and the methods for detecting, preventing and treating it 
should be mandatory. Screening of populations at high risk, in 
order to provide early diagnosis and staging of NAFLD, may also 
be carried out by means of simple laboratory tests and ultrasound 
scans. Early detection of MetS and diabetes and prompt man-
agement of these illnesses remain significant ways for prevent-
ing evolution to liver disease and its ominous severe forms.180,181
Regarding the role of bariatric surgery in relation to the clini-
cal course of NAFLD, many questions remain to be answered. 
Since there is a lack of randomized controlled trials, no ultimate 
conclusions can yet be provided. It is clear that the overall impact 
of bariatric surgery on NAFLD is positive, but the optimal surgical 
technique remains to be determined, as do the longer-term effects 
and the ways of maintaining the benefits achieved. Since there is also 
concern regarding the onset of persistent IR or even re-emergence 
of IR and T2DM182,183 among individuals who initially presented 
complete reversal, further research is needed in order to determine 
the influence of this event on liver histology. Another longer-term 
concern is the prevalence of weight regain, which may also have a 
significant effect on NAFLD.
Statement of human and animal rights
All procedures performed in the studies evaluated involving 
human participants were in accordance with the ethical stan-
dards of the institutional and/or national research committee and 
with the 1964 Helsinki declaration and its later amendments or 
comparable ethical standards.
CONCLUSION
The currently available evidence shows that bariatric surgery may 
become the treatment of choice for individuals with NAFLD. 
It is important to emphasize that further research, especially by 
means of randomized controlled trials enrolling larger cohorts of 
individuals, is necessary in order to determine the optimal pro-
cedure for this group of subjects, as well as whether only indi-
viduals with morbid obesity might benefit from the effects of 
metabolic surgery, since there are vast numbers of lean and over-
weight individuals who also present NAFLD.
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